Skip to main content

Advertisement

SpringerLink
Log in

Dosis-Deeskalation der adjuvanten Radiochemotherapie bei HPV-positiven Oropharynxkarzinomen: die MC1273-Phase-II-Studie

Dose de-escalation during adjuvant chemoradiotherapy of HPV-associated oropharyngeal squamous cell carcinoma: the MC1273 phase II study

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ma DJ, Price KA, Moore EJ, Patel SH, Hinni ML, Garcia JJ, Graner DE, Foster NR, Ginos B, Neben-Wittich M, Garces YI, Chintakuntlawar AV, Price DL, Olsen KD, Van Abel KM, Kasperbauer JL, Janus JR, Waddle M, Miller R, Shiraishi S, Foote RL (2019) Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. J Clin Oncol 37(22):1909–1918. https://doi.org/10.1200/JCO.19.00463

    Article  PubMed  PubMed Central  Google Scholar 

  2. Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B (2017) E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN cancer research group. J Clin Oncol 35(5):490–497. https://doi.org/10.1200/JCO.2016.68.3300

    Article  CAS  PubMed  Google Scholar 

  3. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O’Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J, Moleron R, McArdle O, Dyker K, Al Booz H, O’Toole L, Cook A, Husband D, Loo V, Soe W, Aynsley E, Sridhar T, Jankowska P, Joseph M, Geropantas K, Vaidya D, Griffin M, Hartley A, Vijayan R, Hwang D, Harrington K, Pettit L, Whitaker S, De Winton E, Rolles M, Brennan S, Sen M, Mendes R, Forster M, Chan A, Evans M, Buter J, Srinivasan D, Foran B, Nankivell P, Bryant J, Sharma N, Spruce R, Brooks J, Batis N, Roques T, Bidmead M, Yang H, Nutting C, Tyler J, Henderson J, Baines H, Gasnier A, Miles E, Clark C, Evans M (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393(10166):51–60. https://doi.org/10.1016/S0140-6736(18)32752-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393(10166):40–50. https://doi.org/10.1016/S0140-6736(18)32779-X

    Article  CAS  PubMed  Google Scholar 

  5. Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K (2014) Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 32(23):2486–2495. https://doi.org/10.1200/JCO.2013.53.9163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. https://doi.org/10.1056/NEJMoa0912217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP (2013) Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31(23):2854–2860. https://doi.org/10.1200/JCO.2012.47.7802

    Article  CAS  PubMed  Google Scholar 

  8. Zhang Q, Wu Q, Harari PM, Rosenthal DI (2019) Randomized phase II/III confirmatory treatment selection design with a change of survival end points: statistical design of Radiation Therapy Oncology Group 1216. Head Neck 41(1):37–45. https://doi.org/10.1002/hed.25359

    Article  PubMed  Google Scholar 

  9. Huang SH, Perez-Ordonez B, Liu FF, Waldron J, Ringash J, Irish J, Cummings B, Siu LL, Kim J, Weinreb I, Hope A, Gullane P, Brown D, Shi W, O’Sullivan B (2012) Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 82(1):276–283. https://doi.org/10.1016/j.ijrobp.2010.08.031

    Article  PubMed  Google Scholar 

  10. List MA, Rutherford JL, Stracks J, Pauloski BR, Logemann JA, Lundy D, Sullivan P, Goodwin W, Kies M, Vokes EE (2004) Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck 26(2):163–170. https://doi.org/10.1002/hed.10367

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Freiburg University Medical Center, Robert-Koch-Straße 3, 79106, Freiburg, Deutschland

    Alexander Rühle M.D. &  Nils H. Nicolay M.D., Ph.D.

  2. German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (dkfz), Heidelberg, Deutschland

    Alexander Rühle M.D. &  Nils H. Nicolay M.D., Ph.D.

Authors
  1. Alexander Rühle M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nils H. Nicolay M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Alexander Rühle M.D. or Nils H. Nicolay M.D., Ph.D..

Ethics declarations

Interessenkonflikt

A. Rühle und N.H. Nicolay geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Ma DJ, Price KA, Moore EJ, et al (2019) Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. J Clin Oncol 37:1909–1918

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rühle, A., Nicolay, N.H. Dosis-Deeskalation der adjuvanten Radiochemotherapie bei HPV-positiven Oropharynxkarzinomen: die MC1273-Phase-II-Studie. Strahlenther Onkol 195, 1110–1112 (2019). https://doi.org/10.1007/s00066-019-01527-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01527-5

Search

Navigation